Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares some insights into how bispecifics are changing the lymphoma treatment landscape, highlighting the promise of agents including epcoritamab and glofitamab. Prof. Jäger also discusses the promising results observed in clinical trials and the importance of investigating the long-term use of these agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
The post An insight into how bispecifics are changing the lymphoma treatment landscape appeared first on VJHemOnc.